FDPS Inhibitors

Ibandronate sodium salt acts as a selective inhibitor of farnesyl diphosphate synthase (FDPS) through its unique ability to form stable complexes with the enzyme. This compound exhibits distinct kinetic properties, allowing for a prolonged interaction that effectively disrupts the enzyme's normal function. Its structural features promote specific molecular recognition, influencing the enzyme's conformational state and ultimately impacting downstream metabolic processes.

Lonafarnib is a synthetic compound that acts as a competitive inhibitor of FDPS. It specifically targets the farnesyl pyrophosphate (FPP) binding site of the enzyme, blocking the synthesis of FPP and downstream isoprenoids. Lonafarnib has been investigated as a potential anticancer agent.

BMS 214662 is a small molecule FDPS inhibitor that has shown antitumor activity in research studies. It disrupts the synthesis of isoprenoid compounds.

Zarnestra, also known as tipifarnib, is a FDPS inhibitor that is being researched for its use in regard certain cancers. It acts by inhibiting the farnesylation of proteins involved in cell signaling pathways, thereby interfering with tumor growth and survival.

NVP-BKM120 is a selective inhibitor of the PI3K/Akt signaling pathway and has also been found to inhibit FDPS activity. It targets multiple components of the PI3K pathway, including FDPS, to disrupt cell survival and proliferation in cancer cells.